T, DDP, MC, UK.2023-06-272023-06-272023-04T DD, P M, C UK. . Seroprevalence of hepatitis B, hepatitis C, and human immunodeficiency virus in hemophilia A patients: A descriptive study. National Journal of Physiology, Pharmacy and Pharmacology. 2023 Apr; 13(4): 841-8442231-32062320-4672http://imsear.searo.who.int/handle/123456789/218021Background: Hemophilia A (Factor VIII deficiency) is a X-linked coagulopathy that affects approximately 1/10,000 male live births. In the past, the treatment of hemophilia A consisted of cryoprecipitated plasma and purified factor preparations. As a result, they experienced unusually high incidence of hepatitis and human immunodeficiency virus (HIV) seroconversion. Aims and Objectives: The aims of this study were to find out the seroprevalence of hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV infection, among hemophiliacs attending a tertiary care center in Kerala, southern India. Materials and Methods: A cross-sectional study was conducted on hemophilia A patients who attended the departments of medicine and paediatrics. Demographic details and treatment history were obtained by questionnaire. Enzyme-linked immunosorbent assay was used to detect HBV surface antigen, HCV antibodies, and HIV. The statistical data analysis was performed using SPSS software version. Results: Out of 90 hemophilia A patients who underwent testing for the seroprevalence of transfusion-transmitted viral infections, one (1.1%) patient tested positive for HIV, two (2.2%) for HCV, and one (1.1%) for HBV. Among patients with hemophilia A, the prevalence of transfusion-transmitted infection was 4.4%. Patients with HIV- and HCV-positive tests belonged to the severe hemophilia A group. Moreover, the HBV-positive patient belonged to moderate hemophilia A. Conclusion: The present paradigm of management of hemophilia A patients is with plasma-derived or recombinant Factor VIII concentrates, cryoprecipitates, and fresh frozen plasma. Due to the risk, however remote, of transfusion-transmitted viral infections, all hemophiliacs should receive the hepatitis B vaccine and undergo routine testing for HIV, HCV, and HBV viruses.Factor VIII ConcentratesHemophilia A, SeroprevalenceCryoprecipitated Anti-hemophilic FactorTransfusion-transmitted Viral InfectionsJournal ArticleIndiaDepartment of Transfusion Medicine, Government Medical College, Thiruvananthapuram, Kerala, IndiaDepartment of Transfusion Medicine, Government Medical College, Kollam, Kerala, IndiaDepartment of Transfusion Medicine, Sree Mookambika Institute of Medical Sciences, Kulasekharam, Tamil Nadu, India